178 related articles for article (PubMed ID: 26281685)
1. [Kinase inhibitors and their resistance].
Togashi Y; Nishio K
Nihon Rinsho; 2015 Aug; 73(8):1323-9. PubMed ID: 26281685
[TBL] [Abstract][Full Text] [Related]
2. Targeting receptor tyrosine kinases in solid tumors.
Zhang J; Hochwald SN
Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
[TBL] [Abstract][Full Text] [Related]
3. Dissecting kinase signaling pathways.
Boyle SN; Koleske AJ
Drug Discov Today; 2007 Sep; 12(17-18):717-24. PubMed ID: 17826684
[TBL] [Abstract][Full Text] [Related]
4. [Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Kato S
Nihon Rinsho; 2015 Aug; 73(8):1398-402. PubMed ID: 26281696
[TBL] [Abstract][Full Text] [Related]
5. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Deslandres M; Sibaud V; Chevreau C; Delord JP
Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
[TBL] [Abstract][Full Text] [Related]
6. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
7. Protein kinases as drug targets in cancer.
Arslan MA; Kutuk O; Basaga H
Curr Cancer Drug Targets; 2006 Nov; 6(7):623-34. PubMed ID: 17100568
[TBL] [Abstract][Full Text] [Related]
8. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
9. [Kinase inhibitors].
Yamori T; Kong D
Nihon Rinsho; 2010 Jun; 68(6):1059-66. PubMed ID: 20535956
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic agents and the skin: An update.
Heidary N; Naik H; Burgin S
J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
[TBL] [Abstract][Full Text] [Related]
11. [Molecular targeted therapy for malignant brain tumors].
Okamura T; Kurisu K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():520-6. PubMed ID: 16201575
[No Abstract] [Full Text] [Related]
12. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
13. [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Pérez López G; Carrasco De La Fuente M; Menacho Román M; González Albarrán O; Cano Megías M
Endocrinol Nutr; 2011 Feb; 58(2):94-6. PubMed ID: 21333617
[No Abstract] [Full Text] [Related]
14. Tyrosine kinase inhibitor-induced macrocytosis.
Schallier D; Trullemans F; Fontaine C; Decoster L; De Greve J
Anticancer Res; 2009 Dec; 29(12):5225-8. PubMed ID: 20044640
[TBL] [Abstract][Full Text] [Related]
15. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Hagymási K; Tulassay Z
Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
[TBL] [Abstract][Full Text] [Related]
16. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Kitagawa D; Gouda M; Kirii Y; Sugiyama N; Ishihama Y; Fujii I; Narumi Y; Akita K; Yokota K
J Biochem; 2012 Jan; 151(1):47-55. PubMed ID: 21880693
[TBL] [Abstract][Full Text] [Related]
17. From genome to drugs: where do we stand?
Schmidt C
J Natl Cancer Inst; 2011 Jul; 103(13):996-7. PubMed ID: 21693728
[No Abstract] [Full Text] [Related]
18. [The mechanisms of the resistance to molecular targeting agents].
Akiyama S
Nihon Rinsho; 2004 Jul; 62(7):1297-304. PubMed ID: 15283147
[TBL] [Abstract][Full Text] [Related]
19. [Targeted drugs in radiation therapy].
Favaudon V; Hennequin C
Cancer Radiother; 2004 Nov; 8 Suppl 1():S114-20. PubMed ID: 15679256
[TBL] [Abstract][Full Text] [Related]
20. [Molecular target therapy for malignant tumors].
Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
[No Abstract] [Full Text] [Related]
[Next] [New Search]
